Stock NVS NOVARTIS AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Novartis AG Nyse

Equities

NVS

US66987V1098

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-06-06 pm EDT 		Pre-market 08:36:56 am
106.1 USD +0.73% Intraday chart for Novartis AG 106.4 +0.23%
02:31pm Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy MT
06:43am Novartis, Roche's Genentech Among Companies Facing Italian Competition Watchdog Inquiry Over Eye Drug MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 214,715 215,682 196,476 194,400 207,226 217,273 - -
Enterprise Value (EV) 1 230,615 240,182 204,667 203,434 219,237 229,339 227,883 222,009
P/E ratio 30.4 x 26.7 x 8.2 x 28.3 x 14.1 x 20.8 x 18 x 16.5 x
Yield 3.19% 3.56% 3.83% 3.87% 3.79% 3.41% 3.53% 3.75%
Capitalization / Revenue 4.53 x 4.43 x 3.81 x 3.85 x 4.56 x 4.42 x 4.24 x 4.19 x
EV / Revenue 4.86 x 4.94 x 3.96 x 4.02 x 4.82 x 4.67 x 4.45 x 4.28 x
EV / EBITDA 14.6 x 14.3 x 11.2 x 10.9 x 12.2 x 11.9 x 11 x 10.4 x
EV / FCF 17.9 x 20.5 x 15.4 x 17 x 16.6 x 16.6 x 14.8 x 13.7 x
FCF Yield 5.58% 4.87% 6.49% 5.87% 6.01% 6.03% 6.75% 7.31%
Price to Book 3.87 x 3.78 x 2.9 x 3.23 x 4.42 x 4.72 x 4.67 x 4.36 x
Nbr of stocks (in thousands) 2,264,608 2,274,506 2,237,092 2,150,980 2,055,460 2,040,406 - -
Reference price 2 94.81 94.83 87.83 90.38 100.8 106.5 106.5 106.5
Announcement Date 1/29/20 1/26/21 2/2/22 2/1/23 1/31/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 47,445 48,659 51,626 50,545 45,440 49,126 51,263 51,917
EBITDA 1 15,809 16,845 18,246 18,613 17,937 19,244 20,779 21,271
EBIT 1 14,112 15,416 16,588 16,665 16,372 18,187 19,323 19,678
Operating Margin 29.74% 31.68% 32.13% 32.97% 36.03% 37.02% 37.69% 37.9%
Earnings before Tax (EBT) 1 8,940 9,878 26,137 8,371 9,123 13,129 14,541 15,277
Net income 1 7,147 8,072 24,021 6,955 14,854 10,445 11,687 12,644
Net margin 15.06% 16.59% 46.53% 13.76% 32.69% 21.26% 22.8% 24.35%
EPS 2 3.120 3.550 10.71 3.190 7.150 5.112 5.903 6.457
Free Cash Flow 1 12,875 11,691 13,282 11,945 13,179 13,834 15,386 16,219
FCF margin 27.14% 24.03% 25.73% 23.63% 29% 28.16% 30.01% 31.24%
FCF Conversion (EBITDA) 81.44% 69.4% 72.79% 64.18% 73.47% 71.89% 74.04% 76.25%
FCF Conversion (Net income) 180.15% 144.83% 55.29% 171.75% 88.72% 132.44% 131.65% 128.27%
Dividend per Share 2 3.025 3.375 3.360 3.500 3.823 3.628 3.762 3.988
Announcement Date 1/29/20 1/26/21 2/2/22 2/1/23 1/31/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 13,229 12,531 12,781 12,543 12,690 12,953 13,622 11,782 11,423 11,829 12,257 12,470 12,667 12,260 12,510
EBITDA 4,274 4,407 4,989 4,783 4,473 - 4,668 - 4,224 - - - - - -
EBIT 1 3,819 4,083 4,270 4,282 4,030 4,413 4,668 4,405 3,821 4,537 4,623 4,750 4,543 4,980 4,920
Operating Margin 28.87% 32.58% 33.41% 34.14% 31.76% 34.07% 34.27% 37.39% 33.45% 38.35% 37.72% 38.09% 35.87% 40.62% 39.33%
Earnings before Tax (EBT) 1 16,951 2,669 2,042 1,919 1,741 2,740 2,769 1,552 2,377 3,129 3,856 3,879 3,664 - -
Net income 1 16,308 2,222 1,695 1,575 1,466 2,293 2,316 1,513 8,480 2,688 2,777 2,814 2,515 - -
Net margin 123.27% 17.73% 13.26% 12.56% 11.55% 17.7% 17% 12.84% 74.24% 22.72% 22.65% 22.56% 19.86% - -
EPS 2 7.290 1.000 0.7700 0.7300 0.6900 1.090 1.110 0.7300 4.140 1.310 1.358 1.386 1.252 - -
Dividend per Share 2 3.360 - - - 3.500 - - - 3.823 - 0.9727 0.9727 0.9727 1.039 1.039
Announcement Date 2/2/22 4/26/22 7/19/22 10/25/22 2/1/23 4/25/23 7/18/23 10/24/23 1/31/24 4/23/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 15,900 24,500 8,191 9,034 12,011 12,066 10,610 4,737
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.006 x 1.454 x 0.4489 x 0.4854 x 0.6696 x 0.627 x 0.5106 x 0.2227 x
Free Cash Flow 1 12,875 11,691 13,282 11,945 13,179 13,834 15,386 16,219
ROE (net income / shareholders' equity) 17.5% 23.5% 22.7% 21% 25.4% 32.9% 38.5% 37.6%
ROA (Net income/ Total Assets) 8.89% 6.45% 10.9% 10.7% 12.4% 10.5% 12.3% 14.2%
Assets 1 80,393 125,215 221,201 64,915 120,082 99,179 94,765 88,960
Book Value Per Share 2 24.50 25.10 30.30 28.00 22.80 22.60 22.80 24.40
Cash Flow per Share 2 5.880 5.950 6.670 6.480 6.910 7.790 8.430 8.720
Capex 1 2,257 1,275 1,378 1,198 1,060 1,195 1,271 1,325
Capex / Sales 4.76% 2.62% 2.67% 2.37% 2.33% 2.43% 2.48% 2.55%
Announcement Date 1/29/20 1/26/21 2/2/22 2/1/23 1/31/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Novartis AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
106.5 USD
Average target price
110.2 USD
Spread / Average Target
+3.47%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+43.64% 754B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.47% 630B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.58% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.72% 331B
ABBVIE INC. Stock AbbVie Inc.
+8.78% 298B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.51% 250B
ROCHE HOLDING AG Stock Roche Holding AG
-0.29% 216B
AMGEN INC. Stock Amgen Inc.
+6.13% 164B
PFIZER, INC. Stock Pfizer, Inc.
+0.03% 163B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. NVS Stock
  5. Financials Novartis AG